Navigation Links
Study in the New England Journal of Medicine Shows Non-Surgical Treatment for Pre-Cancerous Condition of Esophagus is Effective and Reduces Risk for Cancer Development
Date:5/27/2009

-grade dysplasia or high-grade dysplasia, and then finally cancer. The present study included patients with the later stages of low- and high-grade dysplasia.

Beginning in 2006, the AIM Dysplasia Trial enrolled 127 patients having a diagnosis of Barrett's esophagus with dysplasia, the most advanced stage of this condition. Patients were randomly assigned to receive either endoscopic ablation with the HALO system or a sham intervention (control, no treatment). Tissue samples (biopsies) were obtained from the esophagus at regular intervals for one year after enrollment to assess for the presence of early Barrett's, dysplasia, and esophageal cancer. Comparison of the biopsy results at one year served as the primary outcome for the trial. The study endpoints were the eradication of all early Barrett's and, separately, all dysplasia in each group, as well as occurrence of new esophageal cancers.

At one-year follow-up, patients treated with ablation had a significantly higher complete eradication rate for both early Barrett's and dysplasia as compared to the control group. More than three quarters of treated patients had no detectable Barrett's at the end of the treatment period, compared to sham patients where 98% had persistent disease. The overall rate of disease progression to more severe forms of dysplasia and cancer was significantly lower in the ablation treatment group (3.6%) as compared to the control group (16.3%). In the highest risk cohort (high-grade dysplasia), ablative therapy significantly reduced the risk of progression to cancer by nearly 90% compared to control (2.4% in treated patients versus 19.0% in untreated controls).

About BARRX Medical, Inc.

BARRX Medical, Inc. develops treatment solutions for Barrett's esophagus, a precancerous condition of the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or GERD. Its main product, the HALO
'/>"/>

SOURCE BARRX Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R)
2. New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
3. New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
4. Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
5. New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease
6. Study Confirms Effectiveness of Innovative Prism Glasses For Hemianopia Patients
7. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
8. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
9. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
10. VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful
11. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) ... 2014 financial results on Wednesday, October 29, 2014, after ... announcement, members of the management team will host a ... a general corporate update at 4:30 p.m. EDT (1:30 ... as follows: Wednesday, October 29 1:30 ...
(Date:10/18/2014)... 18, 2014  In a policy paper ... the nation,s largest lesbian, gay, bisexual and transgender ... of Truvada for Pre-Exposure Prophylaxis (PrEP). PrEP is ... prevent the spread of a disease or infection ... name anti-HIV drug combination currently approved for PrEP, ...
(Date:10/17/2014)... AUSTIN, Texas , Oct. 17, 2014  Hanger, ... it plans to report its results of operations for ... 6, 2014 after the market closes.  A conference call ... 9:00 a.m., ET, on Friday, November 7, 2014. Those ... be available until Friday, November 14, 2014 by dialing ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3
... International, Inc. (NYSE: VRX ) (TSX: ... ALXA ) has received a Complete ... Drug Administration (FDA) regarding Alexza,s New Drug Application ... Staccato® (loxapine) inhalation aerosol, 5 mg and 10 ...
... Oct. 8 Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: ... will assume the position of Chief Executive Officer following the ... and as a Director, effective November 1, 2010, due to ... to thank Mr. Doshi for his many contributions during his ...
Cached Medicine Technology:Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA 2Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA 3Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as G. P. Singh to Assume Position of CEO Effective November 1, 2010 and Update on Remediation Status 2Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as G. P. Singh to Assume Position of CEO Effective November 1, 2010 and Update on Remediation Status 3Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as G. P. Singh to Assume Position of CEO Effective November 1, 2010 and Update on Remediation Status 4
(Date:10/20/2014)... Dunbridge, Ohio (PRWEB) October 20, 2014 ... 50 years, takes pride in manufacturing top-of-the-line absorbent products. ... the image of its most popular brand, Tranquility® Premium ... logo, created a new website, gave its packaging a ... to bring the brand message to the public. , ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked in the ... Every Body Walk! campaign by Kaiser Permanente. Every ... to be more active outside of the workplace. This ... end of September, was a friendly competition between organizations across ... companies gave their staff pedometers and each day, for the ...
(Date:10/20/2014)... Cleveland, Ohio (PRWEB) October 20, 2014 Unveiled ... Affairs’ new Strategic Direction Scorecard conservatively estimates member hospital ROI ... dollar spent on dues, The Center provides $12.50 in value ... ROI is (Member Value – Member Dues)/Member Dues. , ... get at this number and we think the methodology is ...
(Date:10/20/2014)... Maryland, USA (PRWEB) October 20, 2014 ... to track interventions? Here comes a wonderful app Metassessor ... mobile app development company helped its client “Intervention ... more efficiently. The app is designed for iOS 4.3 ... iPod touch. This app is optimized for iPhone 5. ...
(Date:10/19/2014)... York (PRWEB) October 19, 2014 Dr. ... Population Fund, welcomes news of a ceasefire agreement that ... more than 200 girls who were kidnapped from the ... have languished in captivity long enough, and it is ... and communities," stated Dr. Osotimehin. , "We owe it ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... years later, study finds , MONDAY, Sept. 14 (HealthDay ... go into combat are more likely to develop high ... serve in supporting roles, a new military study finds. ... a unique risk factor for newly reported hypertension," Nisara ...
... weakened immune systems should worry, study says , MONDAY, Sept. ... you may want to rethink that daily shower. , New ... a type that can cause lung disease in people whose ... "blasted out of the showerhead and inhaled by the person ...
... ... Louis , ... 2009 -- , , ,WHO: American Association of Radon Scientists and Technologists, , ,WHAT: ... Station Marriott (near Scottrade Center) ,One St. Louis Union Station, , ,WHY: Radon ...
... , , HOPKINTON, Mass., ... ), the world leader in information infrastructure solutions, today ... systems with more than 25,000 healthcare provider customers, has ... EMC, RSA and VMware solutions. As a result, ...
... , , , ITASCA, Ill., ... savings at the JEWEL-OSCO grocery checkout. , , ... pharmacy will receive a special invitation to save a total ... steps to avoid serious complications that can result from certain other illnesses or health ...
... , , LISLE, Ill., ... ten percent of Americans face dangerous drinking water, the Water Quality Association ... , , On Sunday, the newspaper reported results of ... waters." Among its findings: , , Ten ...
Cached Medicine News:Health News:Combat Exposure Tied to Chronic High Blood Pressure 2Health News:Showerheads Harbor a Bounty of Germs 2Health News:Showerheads Harbor a Bounty of Germs 3Health News:21st International Radon Symposium 2Health News:eClinicalWorks Utilizes EMC to Manage Business Expansion and Reduce Costs 2Health News:eClinicalWorks Utilizes EMC to Manage Business Expansion and Reduce Costs 3Health News:JEWEL-OSCO PHARMACY Offers Grocery Savings to Flu Shot Customers 2Health News:Home Filtering Systems Provide Best Drinking Water Protection 2
Cytomegalovirus IgM ELISA....
Microforceps: Diamond Dusted Micro Pic Forceps...
Ultra-fine pointed forceps with diamond dusting on inner tip surface for enhanced grasping of tissue. Ideal for fine membrane grasping....
The Tano Asymmetrical Microforceps features an offset tip which allows optimal visualization along the entire tip length. Versatile tip design targets ILM, fine epiretinal membranes and diabetic or P...
Medicine Products: